Boots buys Clearasil brand for £233m

Click to follow
The Independent Online

Health and beauty retailer,Boots, yesterday unveiled plans to attack the American market with its £233m acquisition of the acne treatment, Clearasil, from the US conglomerate Procter & Gamble.

Health and beauty retailer,Boots, yesterday unveiled plans to attack the American market with its £233m acquisition of the acne treatment, Clearasil, from the US conglomerate Procter & Gamble.

The deal will provide an entry into the over-the-counter market in America and Japan, the first and second largest healthcare markets in the world, for Boots Healthcare International (BHI), the chemist group's division which develops and markets nonprescription medicines.

Clearasil is the world leader in its field of skincare treatment, with £94m of sales in 50 countries. The 50-year-old brand is market leader in eight countries, including the US and the UK.

As well as providing access to markets outside Europe, BHI said the deal would give it a way into the European groceries market.

Boots shares slipped as much as 4p yesterday but closed up 0.5p at 527.5p.

Comments